The risk of developing second primary malignancies in cutaneous melanoma survivors
To the Editor: While some studies have demonstrated an increased risk of subsequent malignancies in melanoma patients, no large-scale population studies have assessed the risk of second primary malignancies (SPMs) after cutaneous melanoma (CM) in the past decade.1-3 Herein, we expanded previous Surveillance, Epidemiology, and End Results database studies to include 194,000 additional subjects to assess the risk of SPM after CM diagnosis.1 Novel to this study is the assessment of SPM risk in CM patients stratified by primary melanoma thickness, initial stage, and patient demographics.
Authors
- Jason B. Lee (ORCID: https://orcid.org/0000-0002-6399-2719)
- Jenna Mandel (ORCID: https://orcid.org/0000-0001-9994-6469)
- Lauren Banner (ORCID: https://orcid.org/0009-0006-2517-7787)
- Tingting Zhan (ORCID: https://orcid.org/0000-0001-9971-4844)
- Rachel Zachian (ORCID: https://orcid.org/0009-0002-4502-7517)
- Safiyyah Bhatti (ORCID: https://orcid.org/0009-0000-0267-1607)
- Neda Nikbakht (ORCID: https://orcid.org/0000-0001-7678-5252)
- Henry Yang (ORCID: https://orcid.org/0009-0002-5266-6878)
- Emily Lee (ORCID: https://orcid.org/0000-0003-0963-6518)
- Thomas Z. Rohan
- Megan O'Donnell-Cappelli
Institutions
- Thomas Jefferson University (US)
- Lankenau Medical Center (US)
- Jefferson Institute (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1016/j.jaad.2024.11.059
- Citations
- 1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- U.S. Department of Veterans Affairs
- Amgen
- Pfizer
- AstraZeneca
- Gilead Sciences
- Biogen
- Office of Research and Development
- Celgene
- University of Pennsylvania
- Lupus Research Alliance
- National Institutes of Health
- Genentech